Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Bovine serum--regulatory issues.

J S Robertson1

  • 1Division of Virology, National Institute for Biological Standards and Control, Blanche Lane, South Mimms, Potters Bar, Hertfordshire EN6 3QG, UK. jrobertson@nibsc.ac.uk

Developments in Biologicals
|March 29, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Use of the nuclear reactor for neutron capture therapy of cancer.

Medical sciences (London, England)·2014
Same author

Changes in nonstructural protein 3 are associated with attenuation in avian coronavirus infectious bronchitis virus.

Virus genes·2011
Same author

Assuring the quality, safety, and efficacy of DNA vaccines.

Methods in molecular medicine·2011
Same author

Dissecting aneurysm of the aorta.

Proceedings. Royal Australasian College of Physicians·2010
Same author

Changes in biological source material.

Biologicals : journal of the International Association of Biological Standardization·2005
Same author

Viruses and assuring viral safety.

Developments in biologicals·2003
Same journal

Review of Ebola virus infections in domestic animals.

Developments in biologicals·2013
Same journal

Ebola: facing a new transboundary animal disease?

Developments in biologicals·2013
Same journal

Opportunities in diagnostic and vaccine approaches to mitigate potential heartwater spreading and impact on the American mainland.

Developments in biologicals·2013
Same journal

Q fever diagnosis and control in domestic ruminants.

Developments in biologicals·2013
Same journal

Schmallenberg virus.

Developments in biologicals·2013
Same journal

Classical swine fever.

Developments in biologicals·2013
See all related articles

Ensuring viral safety in bovine serum for biological products is crucial. Recent EU guidelines focus on infectious bovine polyoma virus and BVDV, but recommendations are relaxing, emphasizing risk analysis for overall serum safety.

Area of Science:

  • Biologics Manufacturing
  • Regulatory Science
  • Veterinary Medicine

Background:

  • USDA 9CFR historically ensured viral safety of bovine serum for biological products.
  • EU regulators have issued new guidelines and the European Pharmacopoeia a monograph on bovine serum use.
  • Harmonization exists, but EU CHMP guidelines highlight infectious bovine polyoma virus and BVDV antibody detection.

Purpose of the Study:

  • To analyze the evolving regulatory landscape for bovine serum in biological product manufacturing.
  • To discuss the implications of EU guidelines on viral safety assessments.
  • To advocate for a risk-based approach to ensure overall viral safety of bovine serum.

Main Methods:

  • Review of current USDA and EU regulations and guidelines.

Related Experiment Videos

  • Analysis of pharmacopoeial standards for bovine serum.
  • Discussion of viral safety testing methodologies and risk assessment principles.

    • Main Results:

    • EU guidelines emphasize infectious bovine polyoma virus and BVDV antibody detection.
    • Regulatory stringency is being relaxed following industry feedback.
    • A comprehensive risk analysis is essential for managing undetected viral contamination.

    Conclusions:

    • Overall viral safety of bovine serum requires a risk-based approach, considering geographical source, inactivation efficacy, and cell culture susceptibility.
    • While regulations evolve, the inherent presence of viruses necessitates ongoing vigilance.
    • Balancing regulatory demands with practical risk management is key for safe biological product manufacturing.